International Clinical Trial: A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP)

Geneva, Aug. 6 -- International Clinical Trials Registry received information related to the study (NCT07729371) titled 'A Safety Study of ST316 in Participants With Familial Adenomatous Polyposis (FAP)' on July 22.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sapience Therapeutics

Condition: Familial Adenomatous Polyposis (FAP)

Intervention: Drug: ST316 IV

Recruitment Status: Not recruiting

Phase: Phase 1

Date of First Enrollment: January 4, 2027

Target Sample Size: 40

To know more, visit https://clinicaltrials.gov/study/NCT07729371

Disclaimer: Curated by HT Syndication....